290 related articles for article (PubMed ID: 23453646)
1. CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives.
Berger LA; Riesenberg H; Bokemeyer C; Atanackovic D
Lung Cancer; 2013 Jun; 80(3):242-8. PubMed ID: 23453646
[TBL] [Abstract][Full Text] [Related]
2. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
Dempke WC; Edvardsen K; Lu S; Reinmuth N; Reck M; Inoue A
Anticancer Res; 2015 Nov; 35(11):5797-806. PubMed ID: 26504000
[TBL] [Abstract][Full Text] [Related]
3. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
[TBL] [Abstract][Full Text] [Related]
4. Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?
Mok T; Yang JJ; Lam KC
J Clin Oncol; 2013 Mar; 31(8):1081-8. PubMed ID: 23401448
[TBL] [Abstract][Full Text] [Related]
5. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer.
Ahluwalia MS; Becker K; Levy BP
Oncologist; 2018 Oct; 23(10):1199-1209. PubMed ID: 29650684
[TBL] [Abstract][Full Text] [Related]
6. AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.
Yang Z; Guo Q; Wang Y; Chen K; Zhang L; Cheng Z; Xu Y; Yin X; Bai Y; Rabbie S; Kim DW; Ahn MJ; Yang JC; Zhang X
Sci Transl Med; 2016 Dec; 8(368):368ra172. PubMed ID: 27928026
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer.
Zhang J; Yu J; Sun X; Meng X
Cancer Lett; 2014 Aug; 351(1):6-12. PubMed ID: 24861428
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
Yi HG; Kim HJ; Kim YJ; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Kim CS; Heo DS; Bang YJ
Lung Cancer; 2009 Jul; 65(1):80-4. PubMed ID: 19059670
[TBL] [Abstract][Full Text] [Related]
9. Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience.
Kato Y; Hotta K; Takigawa N; Nogami N; Kozuki T; Sato A; Ichihara E; Kudo K; Oze I; Tabata M; Shinkai T; Tanimoto M; Kiura K
Cancer Chemother Pharmacol; 2014 May; 73(5):943-50. PubMed ID: 24633759
[TBL] [Abstract][Full Text] [Related]
10. Progression of Central Nervous System Metastases in Advanced Nonsmall Cell Lung Cancer Patients Effectively Treated with First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor.
Yu M; Zhao Q; Li Y; Zhang S; Xu Y; Gong Y; Zhu J; Ding Z; Wang J; Peng F; Wang Y; Huang M; Ren L; Lu Y; Liu Y
Cancer Biother Radiopharm; 2018 Dec; 33(10):421-426. PubMed ID: 31050549
[TBL] [Abstract][Full Text] [Related]
11. Real world impact of epidermal growth factor receptor mutation status on treatment patterns in patients with non-small cell lung cancer.
Sun JM; Rampal S; Lee G; Lee J; Choi YL; Parasuraman B; Guallar E; Cho J; Shim YM
Lung Cancer; 2013 May; 80(2):191-6. PubMed ID: 23384673
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
[TBL] [Abstract][Full Text] [Related]
13. Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC.
Fiala O; Pesek M; Finek J; Benesova L; Bortlicek Z; Minarik M
Neoplasma; 2013; 60(4):425-31. PubMed ID: 23581415
[TBL] [Abstract][Full Text] [Related]
14. Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment.
Becker A; Crombag L; Heideman DA; Thunnissen FB; van Wijk AW; Postmus PE; Smit EF
Eur J Cancer; 2011 Nov; 47(17):2603-6. PubMed ID: 21784628
[TBL] [Abstract][Full Text] [Related]
15. [Research Progress of EGFR-TKI Therapy for Patients with Central Nervous System
Metastases from Non-small Cell Lung Cancer].
Jin Y; Xin T
Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):496-500. PubMed ID: 27561797
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain.
Jamal-Hanjani M; Spicer J
Clin Cancer Res; 2012 Feb; 18(4):938-44. PubMed ID: 22167408
[TBL] [Abstract][Full Text] [Related]
17. Treatment options for EGFR mutant NSCLC with CNS involvement-Can patients BLOOM with the use of next generation EGFR TKIs?
Tan CS; Cho BC; Soo RA
Lung Cancer; 2017 Jun; 108():29-37. PubMed ID: 28625644
[TBL] [Abstract][Full Text] [Related]
18. Integration of EGFR inhibitors and conventional chemotherapy in the treatment of non-small-cell lung cancer.
Pennell NA
Clin Lung Cancer; 2011 Nov; 12(6):350-9. PubMed ID: 21723791
[TBL] [Abstract][Full Text] [Related]
19. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
Ahn MJ; Kim DW; Cho BC; Kim SW; Lee JS; Ahn JS; Kim TM; Lin CC; Kim HR; John T; Kao S; Goldman JW; Su WC; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; Yang JC
Lancet Respir Med; 2017 Nov; 5(11):891-902. PubMed ID: 29056570
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
Park SJ; Kim HT; Lee DH; Kim KP; Kim SW; Suh C; Lee JS
Lung Cancer; 2012 Sep; 77(3):556-60. PubMed ID: 22677429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
